Date: 2017-03-02
Type of information: Collaboration agreement
Compound:
Company: Arix Bioscience (UK) Takeda Ventures (USA - CA))
Therapeutic area: Cancer - Oncology - Gastrointestinal diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details:
- • On March 2, 2017, Arix Bioscience, a global healthcare and life science company supporting medical innovation, announced a strategic agreement with Takeda Ventures.
- The agreement will maximise the complementary skills and experience of both Arix and Takeda across important therapeutic areas. The relationship brings together the unique combination of entrepreneurial business building, investing and industry operating skills at Arix with the deep industry experience of Takeda, to the mutual benefit of both businesses.
- Arix will provide Takeda with access to deal flow and a specialist team across its activities to create and incubate companies in partnership with Takeda, guided by a joint advisory committee comprising five appointees from both companies. Takeda has identified the fields of oncology and gastrointestinology as areas of particular interest.
- Takeda invested in Arix’s recent £100 million (gross) initial public offering on the Main Market of the London Stock Exchange.
Financial terms:
Latest news:
Is general: Yes
